Luis
Montuenga Badía
Catedrático de Universidad
Hospital Universitario Central de Asturias
Oviedo, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (9)
2022
-
Tumor-Intrinsic Nuclear β-Catenin Associates with an Immune Ignorance Phenotype and a Poorer Prognosis in Head and Neck Squamous Cell Carcinomas
International Journal of Molecular Sciences, Vol. 23, Núm. 19
2021
-
Immune cell infiltrates and neutrophil-to-lymphocyte ratio in relation to response to chemotherapy and prognosis in laryngeal and hypopharyngeal squamous cell carcinomas
Cancers, Vol. 13, Núm. 9
-
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3
2020
-
PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas
Cancer Immunology, Immunotherapy, Vol. 69, Núm. 10, pp. 2089-2100
2019
-
The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042
Journal of Clinical Medicine, Vol. 8, Núm. 8
-
The differential impact of SRC expression on the prognosis of patients with head and neck squamous cell carcinoma
Cancers, Vol. 11, Núm. 11
-
YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib
American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899
2018
-
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
The Lancet Respiratory Medicine, Vol. 6, Núm. 10, pp. 771-781
2015
-
Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma
Oral Diseases, Vol. 21, Núm. 7, pp. 899-904